Eisai’s Lenvima gets FDA breakthrough therapy status for renal cell carcinoma

Japanese drugmaker Eisai's US subsidiary has obtained breakthrough therapy status from the US Food and Drug Administration (FDA) for its anticancer agent Lenvima (lenvatinib mesylate) to treat advanced or metastatic renal cell carcinoma.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news